Literature DB >> 20045486

Circulating tumour-derived predictive biomarkers in oncology.

Darren R Hodgson1, Robert Wellings, Maria C M Orr, Rose McCormack, Michael Malone, Ruth E Board, Mireille V Cantarini.   

Abstract

Molecular characterization of tumour material will become increasingly important in selecting patients for clinical trials and offering appropriate treatment for patients in clinical practice. Recent advances in the field have indicated that the molecular characteristics of a tumour can be determined from circulating tumour cells and circulating tumour DNA; thus, a simple blood sample could provide these data in a simple, convenient and efficient manner. This article discusses progress towards guiding treatment decisions through measuring tumour-derived factors in the circulation. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20045486     DOI： 10.1016/j.drudis.2009.12.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  7 in total

Review 1.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.

Authors:  K L Aung; R E Board; G Ellison; E Donald; T Ward; G Clack; M Ranson; A Hughes; W Newman; C Dive
Journal:  Hugo J       Date:  2011-01-30

3.  Plasma tumor DNA: on your markers, get set, go!

Authors:  Hong Yuen Wong; Ben Ho Park
Journal:  Ann Transl Med       Date:  2014-01

4.  Circulating Tumor Nucleic Acids: Perspective in Breast Cancer.

Authors:  Ida Casciano; Angela Di Vinci; Barbara Banelli; Claudio Brigati; Alessandra Forlani; Giorgio Allemanni; Massimo Romani
Journal:  Breast Care (Basel)       Date:  2010-04-23       Impact factor: 2.860

5.  Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.

Authors:  Jean-Yves Douillard; Gyula Ostoros; Manuel Cobo; Tudor Ciuleanu; Rebecca Cole; Gael McWalter; Jill Walker; Simon Dearden; Alan Webster; Tsveta Milenkova; Rose McCormack
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

6.  Multiparametric analysis of cell-free DNA in melanoma patients.

Authors:  Francesca Salvianti; Pamela Pinzani; Paolo Verderio; Chiara Maura Ciniselli; Daniela Massi; Vincenzo De Giorgi; Marta Grazzini; Mario Pazzagli; Claudio Orlando
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

7.  Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma.

Authors:  Francesca Salvianti; Claudio Orlando; Daniela Massi; Vincenzo De Giorgi; Marta Grazzini; Mario Pazzagli; Pamela Pinzani
Journal:  Front Mol Biosci       Date:  2016-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.